AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results | AbbVie

AbbVie has reported its full-year and fourth-quarter 2025 financial results, highlighting record net sales achieved in the second year following the U.S. loss of exclusivity for Humira.

CEO Robert A. Michael described 2025 as an outstanding year that underscores the strength of the company's diversified growth platform despite the Humira expiration.

The company announced adjusted diluted EPS guidance for full-year 2026, projecting a range between $14.37 and $14.57 per share.

This forward guidance explicitly excludes any potential impact from acquired IPR&D and milestone payments incurred during 2026 due to forecasting uncertainty.

Management expects robust growth in 2026 driven by strong fundamentals, innovation investments, and a broadened treatment pipeline for patients.

The full-year results presentation includes both reported GAAP figures and non-GAAP measures to assist investors in evaluating operational performance.

Detailed financial tables for the quarter ended December 31, 2025, provide breakdowns of net revenues, costs of products sold, and selling general and administrative expenses.

Consolidated statements of earnings for the twelve months ended December 31, 2025, detail operating costs including research and development and acquired IPR&D.

Operational comparisons in the financial reports are presented at constant currency rates to reflect prior year's foreign exchange rates for clarity.

Specific revenue notes clarify that figures for Imbruvica international revenues and Epkinly U.S. revenues include profit sharing arrangements.

AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss the fourth-quarter performance and financial results.

The company includes standard forward-looking statement disclosures regarding risks such as intellectual property challenges, competition, litigation, and global macroeconomic factors.

Additional risk uncertainties also cover potential impacts from trade disputes, tariffs, international conflict, and changes in applicable laws and regulations.

An archived edition of the investor call will be available on AbbVie's Investor Relations website after 11:00 a.m. Central Time.

The company continues to focus on therapeutic areas including immunology, neuroscience, oncology, and Allergan Aesthetics as part of its mission.

Bullish Signals
  • AbbVie delivered record net sales in its second full year following the U.S. Humira loss of exclusivity, demonstrating strong performance from its diversified growth platform.
  • CEO Robert A. Michael described 2025 as another outstanding year and stated that the company expects robust growth to continue into 2026.
  • The company advanced promising new treatments and enhanced the breadth and depth of its pipeline through strategic investments in innovation.
  • AbbVie issued forward-looking guidance for full-year 2026 adjusted diluted EPS between $14.37 and $14.57, signaling confidence in future financial performance.
Risk Factors
  • AbbVie's adjusted diluted EPS guidance for full-year 2026 excludes any impact from acquired IPR&D and milestones, which may not be reliably forecasted and introduces significant uncertainty into future earnings projections.
  • The company explicitly warns that forward-looking statements regarding robust growth are subject to risks including challenges to intellectual property, competition from other products, and adverse litigation or government action.
  • Financial results are presented on both reported and non-GAAP bases, requiring investors to reconcile figures that adjust for certain non-cash items and unusual factors rather than relying solely on GAAP metrics.
  • Net foreign exchange loss is highlighted as a specific line item impacting earnings, indicating vulnerability to currency fluctuations.
  • AbbVie undertakes no obligation to revise its forward-looking statements based on subsequent events or developments, leaving investors exposed to unannounced material changes in the company's outlook.
Full Analysis
AbbVie reported its financial results for the fourth quarter and full year 2025, highlighting record net sales achieved in the second full year following the loss of U.S. exclusivity for its key drug, Humira. Robert A. Michael, Chairman and CEO, described 2025 as an outstanding year driven by a diversified growth platform, promising new treatments, and strategic pipeline investments. The company is projecting robust continued growth for 2026 based on strong fundamentals and innovation. For the full year 2026, AbbVie issued adjusted diluted earnings per share (EPS) guidance ranging from $14.37 to $14.57. This forward-looking guidance excludes the impact of acquired intellectual property rights and development expenses (IPR&D) and milestones incurred during the period, as these cannot be reliably forecasted. The release notes that operational comparisons presented in the financial data reflect constant currency rates based on the prior year's foreign exchange rates to ensure fair comparison across periods. The press release details that AbbVie will host an investor conference call starting at 8:00 a.m. Central Time on February 4, 2026, to discuss fourth-quarter performance, with a webcast available through their Investor Relations website. An archived version of the call will be accessible after 11:00 a.m. Central Time. The document also includes standard non-GAAP financial disclosures and cautionary statements regarding forward-looking risks such as intellectual property challenges, competition, R&D difficulties, litigation, regulatory changes, and macroeconomic factors including trade disputes.